Stephen B. Howell, MD, Author at Grand Rounds in Urology

Stephen B. Howell, MD

University of California San Diego, Moores Cancer Center

San Diego, California

Stephen B. Howell, M.D. is a Professor of Medicine at the University of California, San Diego, co-Leader of the Solid Tumor Therapeutics (formerly Tumor Growth, Invasion and Metastasis) Program of the UC San Diego Moores Cancer Center, and Director of the Cancer Therapeutics Training Program. He is a graduate of Harvard Medical School and was trained as a medical oncologist and pharmacologist at the Massachusetts General Hospital, the National Institutes of Health and the Dana Farber Cancer Institute.
Dr. Howell's work focuses on the development of novel drugs and drug delivery systems for the treatment of cancer, and on the molecular and genetic mechanisms underlying the development of drug resistance. He is the author of more than 300 peer-reviewed research papers. Dr. Howell conducted much of the early pharmacokinetic information and clinical trials work on intraperitoneal chemotherapy for the treatment of ovarian cancer. His laboratory has contributed importantly to the current understanding of how the platinum-containing drugs enter, traffic through and exit from ovarian cancer cells, and how such cells become resistant to these drugs.

Disclosures:

Talks by Stephen B. Howell, MD

How to Use Natural Ligands to Kill Tumor Stem Cells

Posted by Stephen B. Howell, MD | Jul 2024

Stephen B. Howell, MD, explores the possibility of using Cancer Stem Cell-Targeted Therapy to fight cancerous tumors and prevent recurrence. He begins with a review of the role of LGR receptors and RSPO ligands in active stem cells.

Dr. Howell then presents data from a trial demonstrating how a particular drug, FcF2-MMAE, can target cancerous tumor cells through a particular LGR receptor. He provides data on FcF2-MMAE’s promising pharmacokinetic and pharmaceutical properties

Dr. Howell concludes by stating that the drug needs to be studied outside of an academic research environment. While most of the academic research has been done on the responsiveness of tumor stem cells in ovarian cancer, he anticipates that the FcF2-MMAE framework may have applications for prostate cancer tumors.

Stephen B. Howell, MD

University of California San Diego, Moores Cancer Center

San Diego, California

Talks by Stephen B. Howell, MD

How to Use Natural Ligands to Kill Tumor Stem Cells

Join the GRU Community

You have Successfully Subscribed!